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crystal-induced cytokine production
through upregulation of suppressor of
cytokine signaling 1 expression
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Abstract
Background: Acute gouty arthritis currently is the most common form of inflammatory arthritis in developed
countries. Treatment is still suboptimal. Dosage of urate-lowering therapy is often too low to reach target urate
levels, and adherence to therapy is poor. In this study, we therefore explore a new treatment option to limit
inflammation in acute gout: specific histone deacetylase (HDAC) inhibition.
Methods: Peripheral blood mononuclear cells (PBMCs) were cultured with a combination of monosodium urate
crystals (MSU) and palmitic acid (C16.0) in order to activate the NLRP3 inflammasome and induce IL-1β production.
HDAC inhibitors and other compounds were added beforehand with a 1-h pre-incubation period.
Results: The HDAC1/2 inhibitor romidepsin was most potent in lowering C16.0+MSU-induced IL-1β production
compared to other specific class I HDAC inhibitors. At 10 nM, romidepsin decreased IL-1β, IL-1Ra, IL-6, and IL-8
production. IL-1β mRNA was significantly decreased at 25 nM. Although romidepsin increased PTEN expression,
PBMCs from patients with germline mutations in PTEN still responded well to romidepsin. Romidepsin also
increased SOCS1 expression and blocked STAT1 and STAT3 activation. Furthermore, experiments with bortezomib
showed that blocking the proteasome reverses the cytokine suppression by romidepsin.
Conclusions: Our results show that romidepsin is a very potent inhibitor of C16.0+MSU-induced cytokines in vitro.
Romidepsin upregulated transcription of SOCS1, which was shown to directly target inflammatory signaling
molecules for proteasomal degradation. Inhibiting the proteasome therefore reversed the cytokine-suppressive
effects of romidepsin. HDAC1/2 dual inhibition could therefore be a highly potent new treatment option for acute
gout, although safety has to be determined in vivo.
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Background
Acute gouty arthritis is an agonizingly painful and debili-
tating disease and is currently the most common form
of inflammatory arthritis in developed countries. Its
prevalence has been rising steadily over the past decades
[1, 2], and it is currently estimated to affect 1–4% of the
general population in most countries in Europe and in
the USA [3–6].
The most important risk factor for the development of
acute gout is hyperuricemia. Urate is a breakdown prod-
uct of purine metabolism, and its levels can be elevated
in the blood due to several causes, including genetic var-
iations in urate transporter genes or a purine-rich diet.
When urate reaches supersaturation in the biologic
fluids or tissues, it precipitates as monosodium urate
crystals (MSU) [7]. Interestingly however, the majority of
hyperuricemic individuals stay asymptomatic throughout
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their life [2], and some patients have normal urate levels
during an acute gout attack [8], indicating that induction
of clinical symptoms by MSU crystals is a process that is
dependent on many factors.
Nevertheless, the main prerequisite for the develop-
ment of acute gout are MSU crystal deposits in the joint.
It has been known for about a decade now that MSU
crystals trigger inflammatory arthritis through activation
of the nucleotide-binding domain and leucine-rich
repeat-containing family, pyrin domain-containing 3
(NLRP3) inflammasome [9]. Assembly of this protein
scaffold activates procaspase-1, which in turn can cleave
inactive pro-IL-1β into its bioactive form. However, for
the initial production of pro-IL-1β, an additional signal
is required, such as IL-1β binding to the IL-1 receptor,
or Toll-like receptor (TLR) ligands. Saturated long-chain
fatty acids, such as palmitic acid (C16.0) and stearic acid
(C18.0), can also provide this first signal and synergize
with MSU crystals to produce large quantities of active
IL-1β [10, 11].
Despite the elaborate knowledge on the pathophysi-
ology of gout and the fact that it is curable, treatment is
still suboptimal in many cases. Dosage of urate-lowering
therapy is often too low to reach target urate levels, and
adherence to therapy is poor among gout patients [12].
Furthermore, many of the comorbidities associated with
gout actually result in contraindications for the currently
available anti-inflammatory medication used in acute
gout [13]. Biologics (recombinant antibodies) blocking
IL-1β are advised in case NSAIDs and colchicine are
contraindicated [12], but they are very costly [14]. In the
current study, we investigated the potential of specific
histone deacetylase (HDAC) inhibitors to suppress
MSU-dependent cytokine production.
HDACs are enzymes capable of removing acetyl
groups from protein lysine residues. With this ability,
they can alter gene expression (when deacetylating his-
tone lysines) or affect the function of non-histone pro-
teins such as transcription factors or other enzymes [15].
The HDAC enzymes are divided into four classes based
on phylogenetic analysis: class I yeast Rpd3-like deacety-
lases (HDAC1, HDAC2, HDAC3, and HDAC8), class II
yeast Hda1-like deacetylases (HDAC4, HDAC5, HDAC6,
HDAC7, HDAC9, HDAC10), class III yeast Sir2-like sir-
tuins (SIRT1, HDAC2, HDAC3, HDAC4, HDAC5,
HDAC6, HDAC7), and class IV deacetylase (HDAC11).
The classical HDACs of classes I, II, and IV and the sir-
tuins of class III make up two distinct families [16, 17].
Together, these enzymes can elicit widespread effects
through changing gene transcription and posttranscrip-
tional modification of proteins.
Next to several naturally occurring HDAC inhibitors,
such as the short-chain fatty acid butyrate and Strepto-
myces-derived trichostatin A [16], a range of synthetic
inhibitors has been developed, with the primary aim of
treating malignancies. The rationale behind this use is
the HDAC-mediated suppression of genes involved in
apoptosis, cell cycle arrest, and tumor suppression [18].
However, in recent years, research has revealed a poten-
tial use of HDAC inhibitors to treat inflammatory
diseases.
In the current study, we attempt to pinpoint the indi-
vidual HDACs that could play a role in acute gouty arth-
ritis by assessing the effects of specific HDAC inhibitors
on C16.0+MSU-induced cytokine production by human
PBMCs in vitro.
Materials and methods
Reagents and inhibitors
MSU crystals were produced in-house from urate (Sigma)
and sodium hydroxide (Merck) as described previously
[11]. Palmitic acid (Sigma) dissolved in 100% ethanol and
human albumin (Albuman 200 g/L, Sanquin, Amsterdam)
were conjugated as described previously [11]. Romidepsin,
entinostat, santacruzamate A, RGFP966, and bortezomib
were purchased from Selleckchem. Etomoxir was pur-
chased from Sigma. HDAC6 inhibitor ITF3107 was kindly
provided by Italfarmaco SpA, Milan, Italy.
PBMC stimulation experiments
Venous blood was drawn from healthy donors or Cowden
syndrome patients. PBMCs were isolated by means of
Ficoll-Paque (GE Healthcare) density gradient centrifuga-
tion. Cells were plated at 0.5 × 106 cells per well in a
U-bottom 96-well plate with Dutch Modified RPMI 1640
medium (Life Technologies) supplemented with 50 μg/mL
gentamycin (Centrafarm), 2mM GlutaMAX, and 1mM
pyruvate (Life Technologies). Cytokine responses to mimic
gout in vitro were induced by adding a combination of
300 μg/mL MSU crystals and 50 μM C16.0. For all experi-
ments, the cells were cultured for 24 h.
Cytokine measurements
Commercially available ELISA kits (R&D Systems) were
purchased for IL-1β, IL-1Ra, IL-6, IL-8, and IL-10 which
were used according to the manufacturer’s protocol.
Intracellular IL-1β and IL-1Ra were determined in the
supernatant of a cell lysate. Cells were lysed using 0.5%
Triton X-100 (Sigma).
Quantitative PCR
RNA was isolated using a phase separation method with
TRIzol reagent (Life Technologies) and chloroform
(Merck) in a 5:1 ratio. Subsequently, the RNA was pre-
cipitated with 2-propanol (Merck). Reverse transcription
into cDNA was performed using iScript cDNA synthesis
kit (Bio-Rad). Quantitative PCR was done using a SYBR
Green PCR master mix (Life Technologies).
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Flow cytometry
Cells were fixed and permeabilized with FIX & PERM Cell
Permeabilization Kit (Invitrogen) and subsequently
stained with CD45-KO (Beckman Coulter) and
p-STAT1-PE or p-STAT3-PE (eBioscience). Samples were
measured on the Beckman Coulter CytoFLEX. During
analysis, cells were gated on being CD45+ to eliminate
debris. Gating on monocyte and lymphocyte populations
was done in the forward versus side scatter plot.
Statistics
All figure panels include ≥ 6 donors divided over at least
two experiments. Conditions were compared to C16.0
+MSU alone (unless stated otherwise in the figures) with a
Wilcoxon signed rank test.
Results
Effects of specific HDAC inhibitors on decreasing C16.0
+MSU-induced IL-1β
Because the first production of IL-1β is of crucial import-
ance for the development of acute gouty arthritis, we tested
the ability of several specific HDAC class I inhibitors to de-
crease its production in PBMCs in response to a
combination of C16.0 and MSU (Fig. 1). In a previous
study, we have shown that broad class I HDAC inhibition
suppresses C16.0+MSU-induced cytokine production, but
specific HDAC8 inhibition did not have a
cytokine-suppressive effect [11]. Here, both romidepsin and
entinostat significantly reduced C16.0+MSU-induced IL-1β
production (Fig. 1a, b). However, the effect of romidepsin
was significantly more potent, decreasing up to 80% of the
IL-1β production, whereas entinostat inhibited up to 34%.
The other specific HDAC inhibitors did not have any effect
on C16.0+MSU-induced IL-1β production.
HDAC1/2 inhibitor romidepsin strongly inhibited C16.0
+MSU-induced cytokines
Due to the potent cytokine-suppressive effects observed
with HDAC1/2 inhibitor romidepsin, we decided to fur-
ther examine its effects. As shown in Fig. 2, already at a
dose as low as 10 nM romidepsin significantly inhibited
IL-1β, IL-6, IL-8, and IL-1Ra production in response to
C16.0+MSU stimulation in PBMCs. In addition, intracel-
lular IL-1β levels were decreased significantly as well
(Fig. 2d). C16.0 alone only slightly increased the produc-
tion of anti-inflammatory IL-10 (Additional file 1: Figure
Fig. 1 Screening of different class I HDAC inhibitors for their suppressive effect on C16.0+MSU-induced IL-1β. Freshly isolated PBMCs from
healthy volunteers were pre-incubated for 1 h with different HDAC inhibitors: a romidepsin (Romi, HDAC1/2 inhibitor), b entinostat (Entino,
HDAC1/3 inhibitor), c Santacruzamate A (SCZM, HDAC2 inhibitor), d RGFP966 (RGFP, HDAC3 inhibitor), and e ITF3107 (ITF, HDAC6 inhibitor). IL-1β
production was induced by adding a combination of 50 μM palmitic acid (C16.0) and 300 μg/mL monosodium urate crystals (MSU) for 24 h. Data
are represented as percentage change compared to the IL-1β production with C16.0+MSU alone
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S1), and there is an insignificant trend towards IL-10 de-
crease when romidepsin is added.
Effects of HDAC1/2 inhibition on cell viability and
transcriptional levels
After determining that romidepsin effectively inhibits
C16.0+MSU-induced cytokine production, we also exam-
ined the transcription of IL-1β and inflammasome-related
genes. In line with previous observations [11], we see that
the combination of C16.0+MSU induces a similar amount
of IL-1ß as is induced by C16.0 alone (Fig. 3a). This sup-
ports the current theory of the two signals that are re-
quired to induce active IL-1ß, as is described in the
introduction. Whereas MSU crystals induce NLRP3 as-
sembly and caspase-1 activation, it has no effect on tran-
scription of pro-IL-1ß. This signal is provided by C16.0.
In Fig. 3a, we show that IL-1β mRNA transcription
was induced dramatically by C16.0-stimulation and was
almost brought back to baseline levels by romidepsin.
mRNA levels of NLRP3 inflammasome components
were not as consistently modified by romidepsin. The
lowest concentration of romidepsin of 10 nM signifi-
cantly decreased CASP1 and increases NLRP3 transcrip-
tion (Fig. 3b, d). The higher concentrations of
romidepsin increased transcription of adaptor protein
ASC (PYCARD) in comparison to C16.0+MSU alone,
but not in comparison to the medium control (Fig. 3e).
Following the drastic decreases in cytokine production
upon addition of romidepsin, we wanted to ensure that
cells were still viable after incubation by means of flow
cytometry with Annexin V (AnV) and propidium iodide
(PI) staining. Neither stimulation with C16.0+MSU nor
addition of romidepsin affected the percentage of live
(Anv and PI negative) cells (Fig. 3c). When looking at
the stratification of early (AnV+PI−) and late (Anv+PI+)
apoptotic cells, only the percentage of late apoptotic
cells was increased with 50 nM romidepsin (Fig. 3f ).
Cytokine-suppressive effects of romidepsin independent
of PTEN mRNA upregulation
In the context of cancer, many research groups have as-
sociated HDAC inhibition with the upregulation of
tumor suppressor phosphatase and tensin homolog
(PTEN) and subsequent inhibition of the phos-
phatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)
pathway [19–22]. As this pathway can play an important
role in cellular metabolic and inflammatory status [23–
25], we assessed whether romidepsin affected PTEN ex-
pression levels. As shown in Fig. 4a, romidepsin signifi-
cantly increased PTEN expression. In addition, mRNA
levels of carnitine palmitoyltransferase IA (CPT1A) were
also significantly elevated by romidepsin (Fig. 4b).
CPT1A shuttles long-chain fatty acids, such as C16.0,
into the mitochondria, comprising the rate-limiting step
in the process of fatty acid oxidation. This process can
be in turn regulated via the Akt signaling pathway [26,
Fig. 2 Suppressive effects of romidepsin on C16.0+MSU-induced cytokine production in human PBMCs. Freshly isolated PBMCs were pre-
incubated with different concentrations of romidepsin for 1 h, after which cytokine production was induced via addition of a combination of
50 μM palmitic acid (C16.0) and 300 μg/mL monosodium urate crystals (MSU). The supernatant was collected for extracellular cytokines (a–c, f).
Cells were lysed with 0.5% Triton X-100, and subsequently, the supernatant of the lysate was collected for measurement intracellular
cytokines (d–e)
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27]. Pre-incubating the cells with etomoxir, an irrevers-
ible CPT1 inhibitor which inhibits fatty acid oxidation
increased the IL-1β production in response to C16.0
+MSU (Fig. 4c). To assess if PTEN upregulation medi-
ates the cytokine-suppressive effects of romidepsin, we
compared its effects in PBMCs from healthy individuals
to the effects in PBMCs isolated from Cowden syndrome
patients, who have a loss of function in the PTEN pro-
tein due to germline mutations. Loss of function in
PTEN, however, did not reverse IL-1β suppression by
romidepsin.
Romidepsin induced SOCS1 expression and inhibited
activation of STAT1 and STAT3
As HDAC1 and HDAC2 act primarily by deacetylating
histones in the nucleus, thereby leading to hyperacety-
lated accessible chromatin, we envisaged that the
cytokine-suppressive effects may be mediated through
upregulation of anti-inflammatory genes. Suppressor of
cytokine signaling (SOCS)1 and SOCS3 are important
negative regulators of inflammation, and their genetic
codes both include binding sites for HDAC1 and
HDAC2 (Fig. 5a). Romidepsin effectively upregulated ex-
pression of SOCS1 (Fig. 5b), but not that of SOCS3
(Fig. 5e). Furthermore, romidepsin inhibited activation
of the inflammatory transcription factors signal
transducer and activator of transcription (STAT)1
(Fig. 5c, d) and STAT3 (Fig. 5f, g).
The proteasome inhibitor bortezomib reverses
romidepsin-induced cytokine-suppression
SOCS1 is known to induce degradation of inflammatory
signaling molecules through the ubiquitin-proteasome
pathway. In particular, it has been shown to induce pro-
teasomal degradation of JAK2, p65, and TIRAP, which
makes it an important negative regulator of TLR signal-
ing pathways [28–30]. The inhibition of cytokine pro-
duction by romidepsin could therefore be induced
through proteasomal degradation. In Fig. 6, we show
that the proteasome inhibitor bortezomib reverses the
romidepsin-induced suppression IL-1β.
Discussion
In this study, we assessed the effects of several specific
HDAC inhibitors in order to pinpoint the HDACs that
could play a role in acute gouty arthritis. In contrast to the
use of HDAC inhibitors in cancer treatment, the
anti-inflammatory effects of HDAC inhibitors are ob-
served at very low concentrations [31]. The HDAC inhibi-
tors givinostat (ITF2357), suberoylanilide hydroxamic acid
(SAHA), and trichostatin-A have been shown to inhibit
joint swelling and cell influx in several different animal
Fig. 3 Effects of romidepsin on cell viability and transcription of IL-1β and NLRP3 inflammasome components. Freshly isolated PBMCs from
healthy donors were pre-incubated with different concentrations romidepsin for 1 h, after which a combination of 50 μM palmitic acid (C16.0)
and 300 μg/mL monosodium urate crystals (MSU) was added to induce cytokine production. After 24 h of culture, mRNA was measured for IL1B
(a), CASP1 (b), NLRP3 (d), and PYCARD (e). Percentages of Annexin V+ and PI+ were measured by flow cytometry to determine cell viability (c, f)
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models of arthritis [32–34]. More importantly, oral ad-
ministration of givinostat was well-tolerated and was
shown to reduce disease activity in patients with juvenile
idiopathic arthritis [35].
However, most of the natural and synthetic HDAC in-
hibitors are broad-acting, blocking most of the classical
HDACs with varying affinity. This may result in opposing
effects on the immune system and cytokine production or
lead to unwanted side effects. To move forward in the
field of HDAC research, it is therefore important to eluci-
date the effects of the individual HDACs and to develop
safe and orally active specific HDAC inhibitors [36, 37].
In the current study, we made use of several specific
synthetic HDAC inhibitors rather than HDAC gene
knockdown for several reasons. Firstly, full genetic
knockout of HDAC1 or HDAC2 in mice has been shown
to be lethal [38, 39]. For HDAC1- or HDAC2-specific
genetic knock-down, we would have to use cell lines.
This is much further from the in vivo situation in
humans than we would like to be. Furthermore, expres-
sion patterns of HDACs are highly tissue-specific [40],
which we envisage will lead to differential effects of
HDAC inhibition in other cell types. Secondly, knock-
down generally does not lead to a 100% inhibition. The
synthetic HDAC inhibitors we use in this study are very
potent and more likely induce HDAC inhibition to a lar-
ger extent than could be achieved by knockdown.
Here, we identify the simultaneous inhibition of
HDAC1 and HDAC2 as a possible new treatment option
in acute gouty arthritis. In previous experiments, we
have shown that class I HDAC inhibition is effective in
suppressing MSU-induced cytokine production. In
addition, we showed that specific HDAC8 inhibition had
no effect [11], leaving HDAC1–3 as possible mediators
of the observed cytokine-suppressive effects. As a single
HDAC enzyme can elicit a wide range of cellular effects,
narrowing down on a specific HDAC to inhibit could be
important to limit side effects. To do this, we tested sev-
eral specific HDAC inhibitors. We observed that romi-
depsin (HDAC1/2 inhibitor) and entinostat (HDAC1/3
inhibitor) effectively reduced the production of MSU
+C16.0-induced IL-1β. In contrast, single inhibition of
HDAC2 or HDAC3 did not affect IL-1β levels. Finally,
we tested a specific HDAC6 inhibitor. Although this is
not a class I HDAC, it has been shown to associate with
microtubules and could interfere with NLRP3 inflamma-
some assembly [41]. Our finding that it does not affect
IL-1β production is in line with a previous paper
Fig. 4 Romidepsin-induced increased expression of PTEN and CPT1A is independent of cytokine suppression. PBMCs from healthy volunteers or
Cowden syndrome patients were pre-incubated for 1 h with several concentrations of romidepsin (Romi) or etomoxir. Cytokine production was
induced by adding a combination of 50 μM palmitic acid (C16.0) and 300 μg/mL monosodium urate crystals (MSU). After 24 h, PTEN (a) and
CPT1A (b) mRNA expression was determined by qPCR. IL-1β production was measured by ELISA after addition of etomoxir (c) or romidepsin in
healthy volunteers and Cowden syndrome patients (d)
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showing that the HDAC6 inhibitor tubastatin did not in-
duce migration of ASC on mitochondria towards NRLP3
on the endoplasmic reticulum [42]. Altogether, these
data suggest that HDAC1 inhibition is capable of block-
ing IL-1β production. Due to the more potent effect of
romidepsin compared to entinostat, we decided to con-
tinue with romidepsin alone.
At a concentration as low as 10 nM, romidepsin
already reduced C16.0+MSU-induced inflammatory cy-
tokines. Furthermore, intracellular levels of IL-1β and
IL-1Ra, as well as IL-1β mRNA levels were decreased.
We ruled out the possibility of cytokine suppression due
to cell death by means of flow cytometry with Annexin
V and propidium iodide staining. The slight increase in
late apoptotic cells with 50 nM of romidepsin is likely
caused by early apoptotic cells dying, as there is no de-
crease in the percentage of live cells. Although the tran-
scriptional levels of NLRP3, CASP1, and PYCARD
seemed to be affected by romidepsin, the effects are
small and do not follow the striking dose-response as is
seen in the cytokine production. There could still be
post-transcriptional changes in the activity of the NLRP3
inflammasome. However, we envisage that this is un-
likely, as we see no accumulation of intracellular IL-1β
upon addition of romidepsin, and because HDAC1 and
HDAC2 mostly affect transcriptional activity in the nu-
cleus. These results suggest that romidepsin blocks
IL-1β production at the level of pro-IL-1β transcription.
A likely candidate to mediate this effect would be the
NF-κB transcription factor. In the canonical pathway,
Fig. 5 Romidepsin induced transcription of SOCS1 and inhibited activation of STAT1 and STAT3. Schematic representations of the SOCS1 and
SOCS3 genome and their binding sites for class I HDACs were retrieved from the USCS Genome Browser by means of the track “Transcription
Factor ChIP-seq (161 factors) from ENCODE with Factorbook Motifs” (a). PBMCs from healthy volunteers were pre-incubated with romidepsin,
after which a combination of 50 μM palmitic acid (C16.0) and 300 μg/mL monosodium urate crystals (MSU) was added. After 24 h, mRNA was
isolated and qPCR was performed for SOCS1 and SOCS3 (b, e). Cells were stained extracellularly with CD45-KO and intracellularly with either p-
STAT1-PE (c, d) or p-STAT3-PE (f, g) for flow cytometry. Gating on CD45+ lymphocytes and monocytes was performed in the forward versus side
scatter graph
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activation of the RelA protein is required to induce
pro-inflammatory gene transcription. However, several
studies have shown that acetylation of RelA in fact
causes increased activation of NF-κB [43–46]. Inhibition
of HDACs would therefore lead to activation of this
transcription factor. This does not fit with the significant
decrease in cytokine production upon addition of romi-
depsin. Therefore, this pathway was not explored further
within the scope of this manuscript.
In the context of cancer, romidepsin has been shown
to interfere with the PTEN/PI3K/Akt pathway [19–22].
This pathway plays a key role in the control of autoph-
agy and cellular metabolism and can indirectly affect the
inflammatory status of the cell [25, 47]. In the current
study, romidepsin indeed increased expression of PTEN,
and also of CPT1A, suggesting a decreased activation of
the PI3K/Akt pathway. However, in the absence of func-
tional PTEN in Cowden syndrome patients, romidepsin
still potently suppressed IL-1β production, indicating
that the cytokine-suppressive effects of romidepsin are
independent of PTEN.
In our search for a possible mechanism of
romidepsin-mediated cytokine suppression, we found
that both SOCS1 and SOCS3 genes possess a binding site
for HDAC1 and HDAC2. Subsequently, we showed that
romidepsin significantly increases gene expression of
SOCS1, but not of SOCS3. In addition, a significant de-
crease in STAT1 and STAT3 phosphorylation was ob-
served in both monocytes and lymphocytes. Naturally,
the decreased activation of STAT1 could be the result of
SOCS1 upregulation. The decrease in STAT3 activation,
however, is independent of SOCS3 and may be mediated
via a romidepsin-induced decrease in IL-6 production.
Several research groups recently established an interest-
ing direct link between SOCS1 and IL-1β. This link in-
volves targeting several inflammatory signaling proteins
for proteasomal degradation [28–30]. To test this path-
way, we studied the effect of proteasome inhibitor borte-
zomib on romidepsin-induced cytokine suppression. We
found that indeed bortezomib was able to reverse the
suppression of IL-1β by romidepsin, indicating that pro-
teasomal degradation is a key mechanism by which
romidepsin exerts its effects.
Romidepsin (Istodax®) was FDA-approved in 2009 for
treatment of cutaneous T cell lymphoma and is adminis-
tered intravenously at 14 mg/m2 over a 4-h period on
days 1, 8, and 15 of a 28-day cycle [48]. We envisage that
a much lower concentration could be used to treat gouty
arthritis. Future in vivo studies will have to show
whether this is a potential treatment option in gouty
Fig. 6 Proteasome inhibitor bortezomib reverses cytokine suppression by romidepsin. PBMCs were isolated from healthy volunteers and were
pre-incubated for 1 h with bortezomib. Then romidepsin was added for 1 h pre-incubation, after which a combination of 50 μM palmitic acid
(C16.0) and 300 μg/mL monosodium urate crystals (MSU) was added for another 24 h. The supernatant was collected for extracellular IL-1β (a).
Cells were lysed with 0.5% Triton X-100, and subsequently, the supernatant of the lysate was collected for intracellular IL-1β measurement (b)
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arthritis. Due to the potent anti-inflammatory effects,
HDAC inhibition may be used in the future to treat
other auto-inflammatory diseases as well.
Additionally, it would be very valuable to study the ef-
fects of romidepsin mechanistically by linking acetyl-
ation events in specific genetic loci to altered
inflammatory gene transcription by means of chromatin
immunoprecipitation and genetic sequencing (ChIP--
seq). We have not performed this in the current study
due to the high costs related to such methods. Alterna-
tively, ChIP-PCR would lack sensitivity for several rea-
sons. Firstly, the current view that HDAC inhibitors
increase histone acetylation and increase gene transcrip-
tion is most likely oversimplified. Genome-wide analyses
revealed increased broad deacetylation conferred by
HDAC inhibitors in vascular endothelial cells, mediated
by the loss of EP300/CREBBP binding [49]. Furthermore,
only one target can be studied at a time with ChIP-PCR.
HDACs have low substrate specificity, and there are sev-
eral histone lysines known to be subject to acetylation
[50]. Studying histone acetylation is further complicated
by the fact that HDAC1 and HDAC2 are present to-
gether in several repressing complexes (NuRD, Sin3a
and co-REST complexes). Finally, there is abundant
cross-talk between different histone modifications, af-
fecting one another [50].
Conclusion
Taken together, we can conclude that inhibition of
HDAC1 and HDAC2 by romidepsin effectively decreases
C16.0+MSU-induced cytokine production. Its effects are
most likely mediated via increased acetylation and subse-
quent increased expression of the SOCS1 gene. SOCS1
is able to directly target inflammatory signaling mole-
cules for proteasomal degradation, which could prevent
the initial transcription of IL-1β. Although romidepsin is
a very potent inhibitor in vitro, more studies are re-
quired before we can achieve HDAC1/2 inhibition dur-
ing a gout flare in patients.
Additional file
Additional file 1: Figure S1. Effects of romidepsin on C16.0+MSU-
induced IL-10 production in human PBMCs. Freshly isolated PBMCs were
pre-incubated with different concentrations of romidepsin for 1 h, after
which cytokine production was induced via addition of a combination of
50 μM palmitic acid (C16.0) and 300 μg/mL monosodium urate crystals
(MSU). The cells were cultured for 24 h. IL-10 concentration was measured
in the supernatant. (PDF 160 kb)
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